Stock ADMA ADMA BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
6.58 USD +0.46% Intraday chart for ADMA Biologics, Inc. +6.13% +45.58%
04-02 ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer CI
03-26 HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics
ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025
ADMA Biologics Taps $135 Million Credit Facility From Debt Refinancing
ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading
ADMA Biologics Obtains US FDA Approval for Plasma Collection Center in Maryland
ADMA Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025
ADMA Biologics, Inc. Appoints Alison C. Finger as Class I Director
Insider Buy: Adma Biologics
Insider Sell: Adma Biologics
Insider Sell: Adma Biologics
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADMA Stock
  4. News ADMA Biologics, Inc.
  5. Other languages